In a preliminary study with a small number of humans, rabbits and mice, researchers at Johns Hopkins Children’s Center say they have developed four new regimens that have the potential to treat and save the lives of people with multidrug-resistant (MDR) tuberculous (TB) meningitis.
In a report that will be published August 14 in Nature Communications, the investigators present the regimens, mainly composed of antibiotics already approved by the U.S. Food and Drug Administration (FDA) for other uses, or antibiotics currently in clinical trials. Study investigators say the regimens could be readily evaluated in new clinical studies or used to treat people with MDR-TB meningitis on a case-by-case basis now.
